{"id":2163,"date":"2026-09-22T01:07:00","date_gmt":"2026-09-21T16:07:00","guid":{"rendered":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-22-vitamin-c-evita-trial-en\/"},"modified":"2026-09-22T01:07:00","modified_gmt":"2026-09-21T16:07:00","slug":"2026-09-22-vitamin-c-evita-trial-en","status":"publish","type":"briefing","link":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-22-vitamin-c-evita-trial-en\/","title":{"rendered":"Phase 2 vitamin C trial in precancerous blood disorders did not change cell progression"},"content":{"rendered":"<p><strong>2026-09-22 01:07 KST<\/strong><\/p>\n<p>EVITA assigned 109 people with precancerous blood disorders or early low-risk blood cancers to vitamin C or placebo for 12 months.<\/p>\n<p>The principal biological progression measure did not improve, and the survival difference was exploratory, so it is not a reason to change supplements without clinical advice.<\/p>\n<h2>Trial design<\/h2>\n<p>Participants in Denmark and the United States were randomised: 55 received 1,000 mg\/day vitamin C and 54 placebo. Treatment was double-blind for 12 months, with follow-up around three years.<\/p>\n<h2>What changed<\/h2>\n<p>The vitamin C group had fewer adverse events and shifts in some inflammatory signals. But the growth rate of abnormal cells, a marker linked to progression, did not differ significantly.<\/p>\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/onepress.co.kr\/wp-content\/uploads\/2026\/09\/vitamin-c-evita-trial-en.png\" alt=\"Phase 2 vitamin C trial in precancerous blood disorders did not change cell progression\" loading=\"lazy\" \/><figcaption class=\"op-briefing-image-caption\">This AI-generated image explains the topic; it is not a photograph of an actual event, observation or field site.<\/figcaption><\/figure>\n<h2>Why the survival signal is cautious<\/h2>\n<p>The roughly three-year survival result came from exploratory analysis. With a small sample and limited events, chance and group differences matter; a confirmatory phase 3 trial is required.<\/p>\n<h2>What readers should do<\/h2>\n<p>Vitamin C does not replace standard care, and high-dose supplements can interact with kidney disease or medicines. Discuss use with a haematology team and wait for the registered EVITA-4 phase 3 results.<\/p>\n<h2>Primary source and independent checks<\/h2>\n<p><a href=\"https:\/\/www.eurekalert.org\/news-releases\/1144084\" target=\"_blank\" rel=\"noopener noreferrer\">CANCER \uc5f0\uad6c \ubc1c\ud45c\uc640 \ub17c\ubb38 \uc815\ubcf4<\/a><\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03682029\" target=\"_blank\" rel=\"noopener noreferrer\">EVITA \uc784\uc0c1\uc2dc\ud5d8 \ub4f1\ub85d NCT03682029<\/a><\/p>\n<p><a href=\"https:\/\/www.cancer.dk\/forskning\/forskning-vi-stoetter\/det-gaar-pengene-til\/landsdaekkende-lodtraekningsstudie-af-oral-c-vitamin-til-patienter-med-tidlig-blodkraeft\/\" target=\"_blank\" rel=\"noopener noreferrer\">3\uc0c1 EVITA-4 \ub3c5\ub9bd \ud6c4\uc18d\uc2dc\ud5d8 \uc548\ub0b4<\/a><\/p>\n<h2>Read in other languages<\/h2>\n<p><a href=\"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-22-vitamin-c-evita-trial-ko\/\">\ud55c\uad6d\uc5b4<\/a> \u00b7 <a href=\"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-22-vitamin-c-evita-trial-en\/\">English<\/a> \u00b7 <a href=\"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-22-vitamin-c-evita-trial-es\/\">Espa\u00f1ol<\/a> \u00b7 <a href=\"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-22-vitamin-c-evita-trial-ja\/\">\u65e5\u672c\u8a9e<\/a> \u00b7 <a href=\"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-22-vitamin-c-evita-trial-vi\/\">Ti\u1ebfng Vi\u1ec7t<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a 109-person randomised phase 2 trial, 1,000 mg of oral vitamin C daily did not significantly change abnormal blood-cell growth. A survival signal at about three years was exploratory and is not proof of treatment benefit before phase 3 confirmation.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-2163","briefing","type-briefing","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing\/2163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing"}],"about":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/types\/briefing"}],"wp:attachment":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/media?parent=2163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}